ProCE Banner Activity

Potential Benefit of Nivolumab Treatment Beyond Progression in Advanced RCC: Subgroup Analysis of CheckMate 025

Slideset Download
Conference Coverage
Nivolumab treatment beyond progression associated with reduced tumor burden, improved OS, and lower incidence of all grade adverse events in patients with advanced RCC.

Released: June 09, 2016

Expiration: June 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals